AAAAAA

   
Results: 1-7 |
Results: 7
Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat
Authors: Lark, MW Stroup, GB Dodds, RA Kapadia, R Hoffman, SJ Hwang, SM James, IE Lechowska, B Liang, XG Rieman, DJ Salyers, KL Ward, K Smith, BR Miller, WH Huffman, WF Gowen, M
Citation: Mw. Lark et al., Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat, J BONE MIN, 16(2), 2001, pp. 319-327
SB-239063, a potent and selective inhibitor of p38 map kinase: Preclinicalpharmacokinetics and species-specific reversible isomerization
Authors: Ward, KW Proksch, JW Azzarano, LM Salyers, KL McSurdy-Freed, JE Molnar, TM Levy, MA Smith, BR
Citation: Kw. Ward et al., SB-239063, a potent and selective inhibitor of p38 map kinase: Preclinicalpharmacokinetics and species-specific reversible isomerization, PHARM RES, 18(9), 2001, pp. 1336-1344
Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic
Authors: Miller, WH Alberts, DP Bhatnagar, PK Bondinell, WE Callahan, JF Calvo, RR Cousins, RD Erhard, KF Heerding, DA Keenan, RM Kwon, C Manley, PJ Newlander, KA Ross, ST Samanen, JM Uzinskas, IN Venslavsky, JW Yuan, CCK Haltiwanger, RC Gowen, M Hwang, SM James, IE Lark, MW Rieman, DJ Stroup, GB Azzarano, LM Salyers, KL Smith, BR Ward, KW Johanson, KO Huffman, WF
Citation: Wh. Miller et al., Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic, J MED CHEM, 43(1), 2000, pp. 22-26
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model
Authors: Miller, WH Bondinell, WE Cousins, RD Erhard, KF Jakas, DR Keenan, RM Ku, TW Newlander, KA Ross, ST Haltiwanger, RC Bradbeer, J Drake, FH Gowen, M Hoffman, SJ Hwang, SM James, IE Lark, MW Lechowska, B Rieman, DJ Stroup, GB Vasko-Moser, JA Zembryki, DL Azzarano, LM Adams, PC Salyers, KL Smith, BR Ward, KW Johanson, KO Huffman, WF
Citation: Wh. Miller et al., Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model, BIOORG MED, 9(13), 1999, pp. 1807-1812
Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist
Authors: Ward, KW Azzarano, LM Bondinell, WE Cousins, RD Huffman, WF Jakas, DR Keenan, RM Ku, TW Lundberg, D Miller, WH Mumaw, JA Newlander, KA Pirhalla, JL Roethke, TJ Salyers, KL Souder, PR Stelman, GJ Smith, BR
Citation: Kw. Ward et al., Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist, DRUG META D, 27(11), 1999, pp. 1232-1241
Identification of metabolites of octamethylcyclotetrasiloxane (D-4) in raturine
Authors: Varaprath, S Salyers, KL Plotzke, KP Nanavati, S
Citation: S. Varaprath et al., Identification of metabolites of octamethylcyclotetrasiloxane (D-4) in raturine, DRUG META D, 27(11), 1999, pp. 1267-1273
Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis
Authors: Lark, MW Stroup, GB Hwang, SM James, IE Rieman, DJ Drake, FH Bradbeer, JN Mathur, A Erhard, KF Newlander, KA Ross, ST Salyers, KL Smith, BR Miller, WH Huffman, WF Gowen, M
Citation: Mw. Lark et al., Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis, J PHARM EXP, 291(2), 1999, pp. 612-617
Risultati: 1-7 |